Skip to main content
Advertisement
Advertisement

PROF

PROF logo

Profound Medical Corp. Common Stock

5.74
USD
Sponsored
-0.15
-2.63%
Sep 23, 16:00 UTC -4
Closed
exchange

After-Market

5.74

0.00
0.00%

PROF Earnings Reports

Positive Surprise Ratio

PROF beat 17 of 42 last estimates.

40%

Next Report

Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$7.17M
/
-$0.23
Implied change from Q2 26 (Revenue/ EPS)
+188.80%
/
-11.54%
Implied change from Q3 25 (Revenue/ EPS)
+35.58%
/
-11.54%

Profound Medical Corp. Common Stock earnings per share and revenue

On Aug 06, 2026, PROF reported earnings of -0.26 USD per share (EPS) for Q2 26, beating the estimate of -0.26 USD, resulting in a 0.99% surprise. Revenue reached 2.48 million, compared to an expected 5.55 million, with a -55.30% difference. The market reacted with a -6.68% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 7.17 million USD, implying an decrease of -11.54% EPS, and increase of 188.80% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Profound Medical Corp. Common Stock reported EPS of -$0.26, beating estimates by 0.99%, and revenue of $2.48M, -55.3% below expectations.
The stock price moved down -6.68%, changed from $7.94 before the earnings release to $7.41 the day after.
The next earning report is scheduled for Nov 11, 2026.
Based on 4 analysts, Profound Medical Corp. Common Stock is expected to report EPS of -$0.23 and revenue of $7.17M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement